Gut microbial signature and gut-lung axis: A possible role in the therapy of COVID-19

Ata Mahmoodpoor; Ali Shamekh; Sarvin Sanaie

doi:10.34172/bi.2021.42

Gut microbial signature and gut-lung axis: A possible role in the therapy of COVID-19

Bioimpacts. 2022;12(2):175-177. doi: 10.34172/bi.2021.42. Epub 2021 Aug 30.

Authors

Ata Mahmoodpoor¹, Ali Shamekh², Sarvin Sanaie³

Affiliations

¹ Anesthesiology and Critical Care Department, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
² Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
³ Neurosciences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.

Abstract

The impact of gut as the origin of different disorders has led to the "gut-origin concept" of diseases. The gut microbiome regulates host defenses against viral infections, thus dysbiosis can play a major role in triggering the cascade of inflammation and causing immune imbalances in COVID-19 patients. It appears that gut microbial signature in COVID-19 patients can be used as a potential diagnostic, therapeutic, and even a prognostic marker. Personalized nutrition therapy can be used by profiling the gut microbiota of individual patients and specialized probiotics/synbiotics to modify gut dysbiosis. Hence, improving overall immune responses can be recommended in these patients.

Keywords: COVID-19; Gut lung axis; Gut microbiota; Probiotics.